• Je něco špatně v tomto záznamu ?

Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity

A. Kodytková, SA. Amaratunga, E. El-Lababidi, I. Čermáková, J. Černá, M. Dvořáková, B. Kalvachová, S. Koloušková, I. Kotvalová, O. Magnová, D. Neumann, D. Novotná, B. Obermannová, R. Pomahačová, Š. Průhová, J. Strnadel, J. Škvor, M. Šnajderová,...

. 2025 ; 38 (5) : 525-532. [pub] 20250314

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015659

OBJECTIVES: Subsequent to early life feeding issues, children with Prader-Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. METHODS: We analyzed height and BMI in 114 patients (58 boys) from REPAR - Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 ± 0.4 years; mean ± SD; early-onset group [EO]), and 45 later (age 7.1 ± 4.1 years; late-onset group [LO]). RESULTS: Height-SDS before therapy was similar in all (EO: -1.9 ± 1.2 [mean ± SD]; LO: -1.7 ± 1.1). After the first year of GH therapy, height-SDS in the EO group increased to -1.0 ± 1.2, in the LO group to -0.9 ± 1.1. After 5 years, height fully normalized in all (-0.1 ± 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 ± 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: -0.9 ± 1.2) and their BMI-SDS increased to the overweight range of 1.3 ± 2.2 (p<0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 ± 2.6) than in LO (3.7 ± 2.2; p<0.001). CONCLUSIONS: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015659
003      
CZ-PrNML
005      
20250731091141.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/jpem-2024-0463 $2 doi
035    __
$a (PubMed)40080424
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kodytková, Aneta $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0009000792814376
245    10
$a Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity / $c A. Kodytková, SA. Amaratunga, E. El-Lababidi, I. Čermáková, J. Černá, M. Dvořáková, B. Kalvachová, S. Koloušková, I. Kotvalová, O. Magnová, D. Neumann, D. Novotná, B. Obermannová, R. Pomahačová, Š. Průhová, J. Strnadel, J. Škvor, M. Šnajderová, Z. Šumník, J. Zapletalová, D. Zemková, K. Kusalová, J. Šilar, J. Lebl
520    9_
$a OBJECTIVES: Subsequent to early life feeding issues, children with Prader-Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. METHODS: We analyzed height and BMI in 114 patients (58 boys) from REPAR - Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 ± 0.4 years; mean ± SD; early-onset group [EO]), and 45 later (age 7.1 ± 4.1 years; late-onset group [LO]). RESULTS: Height-SDS before therapy was similar in all (EO: -1.9 ± 1.2 [mean ± SD]; LO: -1.7 ± 1.1). After the first year of GH therapy, height-SDS in the EO group increased to -1.0 ± 1.2, in the LO group to -0.9 ± 1.1. After 5 years, height fully normalized in all (-0.1 ± 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 ± 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: -0.9 ± 1.2) and their BMI-SDS increased to the overweight range of 1.3 ± 2.2 (p<0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 ± 2.6) than in LO (3.7 ± 2.2; p<0.001). CONCLUSIONS: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.
650    _2
$a lidé $7 D006801
650    12
$a Praderův-Williho syndrom $x farmakoterapie $x komplikace $7 D011218
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dítě $7 D002648
650    12
$a lidský růstový hormon $x terapeutické užití $7 D019382
650    _2
$a předškolní dítě $7 D002675
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a tělesná výška $x účinky léků $7 D001827
650    _2
$a následné studie $7 D005500
650    _2
$a kojenec $7 D007223
650    12
$a morbidní obezita $x prevence a kontrola $x etiologie $7 D009767
650    _2
$a prognóza $7 D011379
650    _2
$a věk při počátku nemoci $7 D017668
650    12
$a obezita dětí a dospívajících $x prevence a kontrola $7 D063766
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Amaratunga, Shenali Anne $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0000000233885824
700    1_
$a El-Lababidi, Eva $u Department of Pediatrics, 3rd Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic $1 https://orcid.org/0000000248399028
700    1_
$a Čermáková, Ivana $u Institute of Endocrinology, Prague, Czech Republic $1 https://orcid.org/0000000162968111
700    1_
$a Černá, Jana $u Department of Pediatrics, Faculty of Medicine, University of Ostrava and University Hospital, Ostrava, Czech Republic $1 https://orcid.org/0009000432127257
700    1_
$a Dvořáková, Marcela $u Department of Pediatrics, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic
700    1_
$a Kalvachová, Božena $u Institute of Endocrinology, Prague, Czech Republic $1 https://orcid.org/0009000452462669
700    1_
$a Koloušková, Stanislava $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0009000213523313
700    1_
$a Kotvalová, Ivana $u Department of Pediatrics, Faculty of Medicine, Charles University and University Hospital, Hradec Králové, Czech Republic $1 https://orcid.org/0009000789982803
700    1_
$a Magnová, Olga $u Department of Pediatrics, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic $1 https://orcid.org/000900062986447X
700    1_
$a Neumann, David $u Department of Pediatrics, Faculty of Medicine, Charles University and University Hospital, Hradec Králové, Czech Republic $1 https://orcid.org/0000000257059113 $7 xx0079752
700    1_
$a Novotná, Dana $u Department of Pediatrics, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic $1 https://orcid.org/0009000719856991
700    1_
$a Obermannová, Barbora $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0009000251267349
700    1_
$a Pomahačová, Renata $u Department of Pediatrics, Faculty of Medicine, Charles University and University Hospital, Plzeň, Czech Republic $1 https://orcid.org/0000000279521364
700    1_
$a Průhová, Štěpánka $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0000000180198026
700    1_
$a Strnadel, Jiří $u Department of Pediatrics, Faculty of Medicine, University of Ostrava and University Hospital, Ostrava, Czech Republic $1 https://orcid.org/0009000755860154
700    1_
$a Škvor, Jaroslav $u Department of Pediatrics, Masaryk Hospital, Ústí nad Labem, Czech Republic $1 https://orcid.org/0009000050320414
700    1_
$a Šnajderová, Marta $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0009000541111270
700    1_
$a Šumník, Zdeněk $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0000000264626462 $7 xx0036973
700    1_
$a Zapletalová, Jirina $u Department of Pediatrics, Faculty of Medicine, Palacky University and Olomouc University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000323335586 $7 jn20000620426
700    1_
$a Zemková, Daniela $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0000000320447910
700    1_
$a Kusalová, Kateřina $u Institute of Biostatistics and Analyzes, s.r.o., Brno, Czech Republic $1 https://orcid.org/0009000030140416
700    1_
$a Šilar, Jiří $u Institute of Biostatistics and Analyzes, s.r.o., Brno, Czech Republic $1 https://orcid.org/000900081290947X
700    1_
$a Lebl, Jan $u Department of Pediatrics, 2nd Faculty of Medicine, 48359 Charles University and Motol University Hospital , Prague, Czech Republic $1 https://orcid.org/0000000233655375 $7 jn19990010093
773    0_
$w MED00180365 $t Journal of pediatric endocrinology & metabolism $x 2191-0251 $g Roč. 38, č. 5 (2025), s. 525-532
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40080424 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091136 $b ABA008
999    __
$a ok $b bmc $g 2366484 $s 1252784
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 38 $c 5 $d 525-532 $e 20250314 $i 2191-0251 $m Journal of pediatric endocrinology & metabolism $n J Pediatr Endocrinol Metab $x MED00180365
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace